Business
Result of GM
Result of GM.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9539D ValiRx PLC 12 July 2016 \n\n \nValiRx Plc\n(\"ValiRx\" or \"the Company\" or \"the Group\")\n \nResult of General Meeting\nLondon, UK, 12 July 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that at the General Meeting of the Company held earlier today to consider a shareholder resolution seeking consent for the dis-application of pre-emptive rights, the resolution was duly passed.\n \n*** ENDS ***\nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\nMark Treharne, Corporate Development Manager\n\n\nTel: +44 (0) 7736 564 686\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\n\nTel: +44 (0) 20 7148 7900\n\n\n\n\nLiam Murray / Jo Turner\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNorthland Capital Partners Limited (Joint Broker)\n\n\nTel: +44 (0) 203 861 6625\n\n\n\n\nPatrick Claridge / David Hignell (Corporate Finance)\nJohn Howes / Abigail Wayne (Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBeaufort Securities Limited (Joint Broker)\n\n\nTel: +44 (0) 207 382 8300\n\n\n\n\nJon Belliss\n\n\n\n\n\n\n\n \nNotes for Editors \nValiRx Plc\nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \nThe Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. \n \nValiRx's two classes of drugs in development, which each have the potential for m...